Global Nasal Vaccines Market Size, Share and Trends Analysis Report, By Type (Flu Vaccines, COVID-19 Vaccines, and Others), By End-user (Adults and Children), Forecast (2022-2028)

The global nasal vaccines market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The global vaccine market is growing due to an increase in respiratory infections, the ongoing COVID-19 epidemic, progress in research and development activities, and rapid clinical trials. Vaccines may be another means of delivering a more effective vaccine, as the composition of the vaccine is better absorbed into the mucous membranes. Nose vaccines protect the area of ​​infection and cause mucosal and systemic immune reactions. The drug manufacturers are developing nasal vaccines such as live antibodies, adjuvants, nanoparticles, mucoadhesives, viral-like particles, DNA vaccines, and lipid-based particles.

Increased respiratory infections caused by Streptococcus, Enterobacteria, and viruses such as Coronavirus, Adenovirus, and Haemophilus influenza promote the growth of the market for nasal decongestants. In addition, the nasal vaccine route improves patient compliance and reduces the need for vaccines to be given to specialist health professionals.

The new technology is expected to improve the growth of the nasal spray industry as the focus is on designing delivery strategies that take into account a wide range of diseases, people, and health care delivery arrangements that will benefit the mucosal delivery line. Significant challenges for the nose vaccine industry include translating in vivo data to clinical outcomes. For instance, Rokote Laboratories Finland Ltd. is preparing to launch the vaccine COVID-19 nasal spray, which uses genetic transfer technology. The technology, developed at the University of Eastern Finland by the team of Professor Seppo Yla-research Herttuala, has already been successfully used in numerous clinical trials on genetic therapy to treat cardiovascular disease. It uses a safe adenovirus carrier with a combined DNA strand that attracts nasopharyngeal cells to produce viral proteins, leading to vaccine response.

India is one of the world’s leading manufacturers and exporters of vaccines and manufacturers are working to produce COVID-19 nasal vaccines. For instance, the Serum Institute of India and Bharat Biotech will launch clinical trials of intranasal COVID-19 in the coming months. Bharat Biotech had signed a license agreement with Washington University School of Medicinefor a single dose of Covid vaccine based on chimp adenovirus.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Abbott, Bharat Biotech, GlaxoSmithKline plc, Sanofi S.A., and Serum Institute of India, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Nasal Vaccines Market Report by Segment

By Type

• Flu Vaccines
• COVID- 19 Vaccines
• Others

By End-user

• Adults
• Children

Global Nasal Vaccines Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa